<DOC>
	<DOCNO>NCT01224678</DOCNO>
	<brief_summary>RATIONALE : Vitamin D may help prevent breast cancer . PURPOSE : This randomized clinical trial study vitamin D breast cancer biomarkers female patient .</brief_summary>
	<brief_title>Vitamin D Breast Cancer Biomarkers Female Patients</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate change mammographic density use Boyd method one year vitamin D supplementation compare placebo premenopausal woman . Secondary - To explore change serum biomarker IGF1 response one year vitamin D placebo supplementation premenopausal woman . - To explore change cellular proliferation ( atypia Ki67 ) response one year vitamin D placebo supplementation premenopausal woman . - To explore correlation change breast cancer biomarkers ( density , IGF1 , atypia , Ki67 ) change vitamin D level . - To compare method mammographic density analysis . - To validate recently develop sunlight questionnaire . OUTLINE : This multicenter study . Patients stratify accord baseline vitamin D ( sufficient [ ≥ 30 ng/mL ≥ 75 mmol/L ] v insufficient [ &lt; 30 ng/mL &lt; 75 mmol/L ] ) institutional random periareolar fine-needle aspiration ( RPFNA ) status ( performs RPFNA v perform RPFNA ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral placebo daily 12 month . - Arm II : Patients receive oral vitamin D ( 2000 IU ) daily 12 month . Tissue blood sample collect baseline 12 month laboratory biomarker analysis . Patients also complete questionnaire baseline 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Premenopausal woman 55 year age young regular menstrual cycle ( least four cycle last six month ) . Women few 4 menses last 6 month hysterectomy ovary intact consider premenopausal FSH level &lt; 20 . 2 . Women breast density ≥ 25 % ( scattered fibroglandular density great ) eligible . 3 . Prior Treatment 1 . Patients currently receive hormone replacement therapy ( estrogen progesterone ) ; take tamoxifen raloxifene eligible . Women take medication must stop least 4 month prior study entry . Topical estrogen ( eg , transdermal patch vaginal estrogen ) allow . 2 . Patients currently use hormonal contraception , take least 4 month prior study entry . 4 . Vitamin D Use 1 . Patients take regular vitamin D supplementation ( 400 IUs daily ) refuse unable stop use eligible . Women agree stop need least 6 month prior registration . 2 . Patients may start vitamin D supplementation registration ( regardless result vitamin D test ) may continue vitamin D already take 400 IUs daily less take vitamin D least 6 month prior baseline mammogram . 5 . Patients history breast cancer ( include DCIS ) ovarian cancer eligible . 6 . Patients history breast implant breast reduction eligible . 7 . Patients two bone fracture past five year eligible . 8 . Patients diagnosis osteoporosis physician recommendation treatment low bone mass eligible . 9 . Patients know hyperparathyroid disease serious disturbance calcium metabolism require intervention past 5 year eligible . 10 . Patients history kidney stone ( unless document calcium stone ) eligible . 11 . Patients participate concurrent breast cancer chemoprevention trial eligible . 12 . Required initial laboratory value Calcium &lt; 10.5 mg/dL</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>breast cancer</keyword>
</DOC>